This 2018 systematic review examined the therapeutic role of alpha-lipoic acid (ALA) in diabetic polyneuropathy (DPN), focusing on efficacy, safety, and cost-effectiveness. Based on 25 studies, including randomized controlled and open-label trials, ALA administered at 600 mg/day—either intravenously or orally—consistently reduced neuropathic symptoms with minimal adverse effects. Mechanistically, ALA exerts
